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Summary The anti-tumour activity of CPT-l1, a topoisomerase I inhibitor, was evaluated in four human
neural-crest-derived paediatric tumour xenografts: one peripheral primitive neuroectodermal tumour (pPNET)
(SK-N-MC) and three neuroblastomas. Two models, SK-N-MC and IGR-N835, were established in athymic
mice from a previously established in vitro cell line. Two new neuroblastoma xenograft models, IGR-NB3 and
IGR-NB8, were derived from previously untreated non-metastatic neuroblastomas. They exhibited the classic
histological features of immature neuroblastoma along with N-myc amplification, paradiploidy, chromosome
lp deletions and overexpression of the human mdrl gene. These tumour markers have been shown to be poor
prognostic factors in children treated for neuroblastoma. CPT- 11 was tested against advanced stage
subcutaneous tumours. CPT- 11 was administered i.v. using an intermittent (q4d x 3) and a daily x 5 schedule.
The optimal dosage and schedule was 40 mg kg-' daily for 5 days. At this highest non-toxic dose, CPT- 11
induced 100% tumour-free survivors on day 121 in mice bearing the pPNET SK-N-MC xenograft. For the
three neuroblastoma xenografts, 38-100% complete tumour regressions were observed with a tumour growth
delay from 38 to 42 days, and anti-tumour activity was clearly sustained at a lower dosage
(27 mg kg-' day-'). The efficacy of five anti-cancer drugs commonly used in paediatric oncology or in
clinical development was evaluated against SK-N-MC and IGR-N835. The sensitivity of these two xenografts
to cyclophosphamide, thiotepa and cisplatin was of the same order of magnitude as that of CPT-11, but they
were refractory to etoposide and taxol. In conclusion, CPT- 11 demonstrated significant activity against pPNET
and neuroblastoma xenografts. Further clinical development of CPT- 11 in paediatric oncology is warranted.
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Neuroblastomas are frequent malignant paediatric solid
tumours, accounting for 6-8% of all malignancies in
children. These tumours arise from the sympathetic tissue,
outside the central nervous system, and belong to the group
of primitive neuroectodermal tumours (PNETs). At diag-
nosis, nearly 50% of neuroblastomas are metastatic, mainly
to the bone marrow. Several biological tumour parameters
such as N-myc gene amplification (Brodeur et al., 1984), loss
of heterozygosity of chromosome lp (Fong et al., 1989;
Hayashi et al., 1989), diploidy (Hayashi et al., 1989) and
mdrl gene overexpression (Bourhis et al., 1989; Chan et al.,
1991) have been identified as strong predictors of a poor
outcome. Despite the use of intensive chemotherapy
protocols, including high-dose chemotherapy followed by
autologous bone marrow stem cell support, the survival of
children treated for non-metastatic neuroblastoma with N-
myc amplification or for metastatic neuroblastoma (over 1
year of age) remains poor.
The group of peripheral PNETs (pPNETs) includes
osseous and extraosseous Ewing's sarcomas along with
neuroepitheliomas. Like neuroblastoma, pPNETs are
neural-crest-derived tumours. The differential morphological
diagnosis between extraosseous pPNETs and neuroblastoma
sometimes proved difficult, until the t(l 1,22) reciprocal
translocation was identified as specific to pPNET (Delattre
et al., 1992). These tumours are chemosensitive but the
prognosis of patients with a metastatic or poorly chemo-
sensitive pPNET remains poor.
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Newactivedrugsare therefore needed toimprovefurtherthe
survivalofpatientswithneuroblastoma andpPNET. CPT-l 1, a
semisynthetic water-soluble analogue ofcampthotecin, belongs
to a new class ofanti-cancer drugs, the DNA-topoisomerase I
inhibitors. These compounds stabilise the cleavable complex
(topoisomerase I-DNA) and induce consecutive lethal events
that lead to cell death (Pommier et al., 1994).
CPT-11 exhibited a wide spectrum ofpreclinical activity in
vivo against murine and human solid tumours (Kunimoto et
al., 1987; Kawato et al., 1991; Bissery et al., 1992; Houghton
et al., 1993). In addition, phase II studies in adults have
shown promising results in several cancers such as colon and
lung cancers (Masuda et al., 1993; Abigerges et al., 1995).
CPT-11 may prove to be an interesting new drug for the
treatment of cancer in children. In order to establish the
rational basis for the clinical development of CPT-11 in
paediatric oncology, we embarked on the preclinical
evaluation of CPT-11 against specific paediatric tumour
xenografts. The aims of the present study were; (1) to
establish and characterise neuroblastoma and pPNET
xenograft models; (2) to evaluate the anti-tumour activity
of CPT-11; (3) to compare the activity of CPT-11 with that
of other anti-cancer drugs.
Materials and methods
Animals
Female SPF-Swiss nude mice were bred in large-sized
isolators in the Animal Experimentation Unit, at the Institut
Gustave-Roussy (Villejuif, France). The strain was obtained
from Carl Hansen (NIH, Bethesda, MD, USA) in 1976.
Animals were housed in sterile isolators, and fed with
irradiated nutrients (UAR, Villemoisson/Orge, France) and
filtered water ad libitum. Experiments were carried out underCPT-11 against nouroblastoma xenografts
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the conditions established by the European Community
(directive no. 86/609/CEE).
Origin and establishment of the paediatric tumour xenograft
models
The SK-N-MC cell line was purchased from the American
Type Culture Collection (Rockville, MD, USA) (ref. HTB
10). This pPNET cell line was established in vitro by Biedler
from a supraorbitary metastasis in a 14-year-old girl
(Biedler et al., 1973). This cell line was originally classified
as a neuroblastoma cell line. Further cytogenetic studies
demonstrated the presence of the t(11,22) translocation,
which is specific to Ewing's sarcoma and other pPNETs
(Chen et al., 1995). The SK-N-MC xenograft model was
established by the subcutaneous injection of 107 cells per
mouse in eight animals, which induced tumour growth in
100% of animals.
IGR-N835 was derived from a previously treated stage IV
abdominal neuroblastoma with N-myc amplification (25
copies/haploid genome) in a 2-year-old girl (Bettan-Renaud
et al., 1989). The patient's tumour proved to be tumorigenic
in six out of seven mice that had been injected
subcutaneously with 107 cells obtained after mechanical
dissociation of the tumour. In addition, a continuous in vitro
cell line was obtained and characterised in terms of
immunocytochemistry, cytogenetics and N-myc gene ampli-
fication and overexpression. An IGR-N835 xenograft
tumour at passage 17 was kindly provided by J Benard
and subsequently maintained in vivo by sequential passages.
IGR-NB3 and IGR-NB8 were derived from two
previously untreated primary neuroblastomas. IGR-NB3
was derived from a stage III abdominal neuroblastoma with
N-myc amplification (27 copies/haploid genome) in a 4-year-
old boy. IGR-NB8 was derived from a stage III abdominal
neuroblastoma with N-myc amplification (five copies/haploid
genome) in a 5-year-old boy. The primary tumours of these
two patients were refractory to conventional chemotherapy
and these children eventually died of disease. Patient tumour
fragments (3 x 3 mm) were obtained at diagnosis and
transplanted subcutaneously in female athymic mice that
had previously received total body irradiation at a dose of
5 Gy ('Co Eldorado). A successful take rate was observed in
seven out of seven and two out of two mice for IGR-NB3
and IGR-NB8 respectively.
Xenografts were maintained in vivo in non-irradiated mice.
Small fragments (3 x 3 mm) were obtained from a 1000-
1500 mm3 tumour, and transplanted subcutaneously into the
flanks of animals. The human origin of the four xenograft
lines was confirmed by the analysis of lactate dehydrogenase
(LDH) isoenzymes (data not shown).
Characterisation ofxenograft models
For histological analysis, fresh xenograft tissue specimens were
fixed in acetic acid-formalin-ethanol (AFA, Carlo-Erba,
Milano, Italy) and embedded in paraffin. The paraffin-
embedded sections were routinely stained with haematoxy-
lin-eosin-saphranine (HES). Immunohistochemical analysis
was then performed using the Dako L.SAB (labelled-
streptavidin-biotin) kit (Dakopatts, Copenhagen, Denmark)
after systematic pretreatment by microwave oven heating in an
appropriate buffer. The following primary antibodies (Dako-
patts) were used: monoclonal neuron-specific enolase (NSE)
diluted 1:40; chromogranine diluted 1: 50; MIC2 diluted 1: 50;
common leucocyte antigen (CLA) diluted 1: 75 as a negative
control. Histological analysis wasperformed foreachxenograft
model at first passage in mice and then every 3-6 passages.
For the cytogenetic study of IGR-NB3 and IGR-NB8,
fragments of fresh xenograft tumours were mechanically
minced. The dissociated cells were then plated in RPMI-1640
medium with 20% fetal calf serum for a short culture. Cells
were harvested after 6-16 h incubation with colcemid
(0.001%). RHG banding was then performed after a
hypotonic shock (potassium chloride 0.075 M for 30 min),
as previously described (Dutrillaux et al., 1971). Twenty
mitoses were analysed for each tumour according to the
ISCN nomenclature.
Southern blot analysis of N-myc and Northern blot
analysis of the human mdrl gene transcript were performed
as described previously (Ferrandis et al., 1994). Genomic
DNAs and RNAs were prepared from freshly frozen
xenograft tumours according to a modified caesium
chloride-guanidium isothiocyanate method. The human N-
myc probe was pNb-1 covering the second exon. Positive
controls consisted of the SK-N-SH neuroblastoma and Y79
retinoblastoma cell lines, which contain one and 25 copies of
N-myc respectively. The human mdrl gene probe was the
complementary DNA probe HDR5A, which encompasses the
coding regions of the gene. The mdrl gene transcript was
measured and compared with that of the KB-8-5 cell line,
which arbitrarily expresses 30 a.u. Qualitative and quantita-
tive controls of the RNA preparations were provided by
ethidium bromide staining whereas Southern blots were
rehybridised with ,B-actin pseudogene.
The presence ofthe EWS-FLI fusion transcript in the SK-
N-MC xenograft was detected by reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis of total RNA,
as described previously (Delattre et al., 1992). Briefly, reverse
transcription of total RNA was carried out with oligonucleo-
tides 1 A, 22A and ERG.A using the Gen Amp RNA PCR kit
(Perkin-Elmer, Saint-Quentin-en-Yvelines, France). Theresult-
ing cDNAs were PCR amplified using either primers 22.8 and
22.5 (for EWS-EWS positive control), ERG11 and 22.8 (for
EWS-ERG) or 11.11 and 22.8 (for EWS-FLI1). The size of
the amplified products was recorded with a 100 bp loader.
Drugs
CPT-11 was kindly provided by the Laboratoire Bellon
(Neuilly-sur-Seine, France). Cyclophosphamide was pur-
chased from Asta-Medica (Merignac, France), thiotepa and
cisplatin from Bellon, etoposide from Sandoz (Rueil-
Malmaison, France) and taxol from Sigma Chimie (Saint-
Quentin, France). All the drugs, except for taxol, were
dissolved in 0.9% sodium chloride solution immediately
before injection on each day of treatment. Taxol was first
dissolved in ethanol, then Cremophor EL (BASF-France,
Nanterre) was added and a final 6% Cremophor EL
suspension was obtained with 5% glucose in water. Drugs
were administered as a 0.2 ml volume of the appropriate
solution per mouse. Mice in the control groups received
0.2 ml of the drug-formulating vehicle with the same schedule
as the treated animals.
Experimental design
Drug activity was evaluated only against advanced-stage
tumours. For each experiment, 3 x 3 mm tumour fragments
were xenotransplanted subcutaneously (unilaterally or bilat-
erally) in 30-50 athymic mice aged 6-8 weeks. On day 0 of
the treatment, mice bearing a 100-300 mm3 subcutaneous
tumour were pooled and randomly assigned to 2-4 groups of
5-10 mice (one control group, 1-3 treated groups at
different dose levels). Animals bearing bilateral tumours
were used only in two experiments (CPT-11 against IGR-
NB3 and taxol against SK-N-MC). Animals with tumours
outside the desired volume range were excluded. Two tumour
perpendicular diameters were measured three times weekly
with a caliper by the same investigator. Each tumour volume
was calculated according to the following equation:
V(rnm3) = d2 (MnM2) x D (mm)/2
where d and D are the smallest and largest perpendicular
tumour diameters respectively. Each group of mice was
treated according to the average weight of the group. Animal
body weights were recorded three times a week and mortalityCPT-11 against neuroblastoma xenografts
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was checked daily. Body weight loss (BWL) was reported as
the maximum treatment-related weight loss. The expreriments
lasted until tumour volumes reached 1500-2000 mm3. The
experiment was stopped after 120 days when there were
tumour free survivors.
Treatment
CPT-1 1 was administered i.v. in a caudal vein at a daily dose
ranging from 27 to 100 mg kg-'. Two schedules were
studied: an intermittent schedule (one dose every 4 days for
a total of three doses, q4d x 3) and a daily x 5 schedule.
Cyclophosphamide and thiotepa were administered once i.p.
at a dose of 400 and 24 mg kg-' respectively. These dosages
represented 90% of the 10% lethal dose (LDIo) of these two
drugs, as previously determined in non-tumour-bearing
female athymic Swiss mice. Etoposide was administered i.v.
daily x 5 at a dose of 17 and 25 mg kg-' day-'. Cisplatin was
administered i.v. on day 0 and day 4 at a dose of 3.5-
10 mg kg-1 day-1. Taxol was administered i.p. over 7 days
at a daily dose ranging from 12 to 20 mg kg-1 over 7 days.
Therapeutic experiments were carried out from passages 3 to
17 for SK-N-MC, from passages 10 to 33 for IGR-N835 and
at passage 5 for IGR-NB3 and IGR-NB8. This study
intended to evaluate the anti-tumour activity of CPT-11,
cisplatin, etoposide and taxol at the highest non-toxic dose,
defined as the dose level that induced no toxicity-related
deaths and a maximum BWL of less than 15%, as observed
in each multiple dose-level experiment. The anti-tumour
activity of cyclophosphamide and thiotepa was evaluated at
90% of the historical LDI0 dosage.
Figure 1 Photomicrographs of the pPNET SK-N-MC (a) and
neuroblastoma IGR-NB3 (b) xenografts after staining with HES.
Original magnification x 400.
Evaluation of anti-tumour activity
The activity of each drug tested was evaluated according to
three criteria: (1) the number of complete and partial tumour
regressions; (2) the tumour growth delay (TGD); (3) the
number oftumour-free survivors (TFSs). Complete regression
(CR) was defined as a tumour regression beyond the palpable
limit (15 mm3) and partial regression (PR) as a tumour
regression greater than 50% of the initial tumour volume.
CR and PR had to be observed for at least two consecutive
tumour measurements in order to be retained. TGD was
defined as the difference between the treated group and the
control group in the median time to reach a tumour volume
that was five times greater than the initial tumour volume
(Friedman et al., 1988). Tumour-free survivors were defined
as animals free of palpable tumour at the end of the
experiment (at least 120 days).
Results
Characterisation of the xenograft models
SK-N-MC xenografts showed the microscopic features of an
immature PNET, namely uniform dense sheets of small
rounded cells with regular nuclei, frequent mitoses and scant
cytoplasm (Figure la). Neither rosette formation nor fibrous
septa were observed. Immunohistochemical analysis showed
negativity for NSE, chromogranine and MIC2. No N-myc
amplification was observed. The diagnosis of pPNET was
ascertained by the presence of the EWS-FLI fusion
transcript as identified by RT-PCR (Figure 2). IGR-N835,
IGR-NB3 and IGR-NB8 showed the classic microscopic
appearance of immature neuroblastomas, namely small
uniform rounded cells more or less arranged in nests that
are separated by a fibrillar stroma (Figure lb). No ganglion
cells were observed. All three xenografts exhibited positivity
for NSE and chromogranine, along with N-myc amplification
(Table I). The previously reported cytogenetic study of IGR-
N835 showed a paradiploid mode with a t(1;10) and t(11;17)
(Bettan-Renaud et al., 1989) (Table I). The IGR-NB3
xenograft was diploid with numerous double minute
chromosomes (DMS) and two recurrent markers, namely
M 1 2 3 4 1 2 3 4 M
800 bp
EWS-EWS
800 bp
EWS-FLI
Figure 2 Identification of the EWS -FLI fusion transcript in
SK-N-MC xenograft by RT-PCR analysis. The cDNAs were
amplified using primers 22.8 and 22.5 as EWS-EWS positive
controls (left) and primers 11.11 and 22.8 for EWS -FLI (right).
Lanes 1 and 2, SK-N-MC xenografts; lane 3, patient tumour with
EWS-ERG transcript; lane 4, PCR-negative control; M, 100bp
loader.
deletion of the short arms of chromosomes 1 and 2 [del(lp)
and del(2p)] (Table I, Figure 3a). No cytogenetic study could
be performed on the patient's tumour. IGR-NB8 was
paradiploid with a del(lp), a pericentric inversion of
chromosome 2 and the addition of material on the long
arm of chromosome 6. One of the breakpoints (2p24) of the
pericentric inversion is implicated in the N-myc gene. The
same chromosome markers were found in the patient's
tumour, surgically removed after chemotherapy (Figure 3b),
strongly suggesting that the chromosome alterations found in
the xenograft were not acquired during xenografting. It was
not possible to check whether the pericentric inversion of
chromosome 2 was constitutional or not because of a
chemotherapy-induced low lymphocyte blood count. Final-
ly, the IGR-NB3 and IGR-NB8 neuroblastoma xenografts
exhibited overexpression of the human mdrl gene whereas the
SK-N-MC and IGR-N835 xenografts did not (Table I).
The tumour take rate of the four xenografts ranged from
81% to 99% (Table I). They showed reproducible growth
kinetics as evaluated by measuring the doubling time and
based on the unchanged histological features throughout the
experiments.CPT-11 against neuroblastoma xenografts
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Toxicity of CPT-JJ in tumour-bearing mice
The optimal dosage and schedule during short-term
administration (intermittent or daily x 5 schedules) were first
studied in animals bearing the SK-N-MC and IGR-N835
xenografts.
During the first experiments, toxicity-related deaths were
observed immediately after the i.v. injection of doses
greater than 45 mg kg-'. These immediate toxicity-related
deaths were dose dependent, with five deaths after eight
injections and two deaths after 23 injections at 100 mg kg-'
and 66 mg kg-' dose levels respectively. This toxicity was
related neither to the speed of injection nor to the vehicle
in which CPT-11 was formulated (D-sorbitol 225 mg, lactic
acid 4.5 mg, sodium hydroxide qsp pH 3.5, in distilled
water qsp 5 ml). Owing to the dose dependent immediate
toxicity, the highest non-toxic dose using an intermittent
schedule was 45 mg kg- day-' q4d x 3 (total dose,
135 mg kg-'). Using the daily schedule, acute toxicity-
related deaths were observed at the 60 mg kg-1 day-' x 5
dose level with five out of eight mice dying on days 7-10.
The optimal dosage was 40 mg kg-1 day-1 x 5 (total dose,
200 mg kg-') with no toxicity-related deaths and a
maximum body weight loss ranging from 0.5% to 11%.
No diarrhoea was observed during any of the experiments.
Animals treated with the dailyx 5 schedule were observed
up to a maximum of 120 days. Out of the 92 mice treated
at dosages ranging from 27 to 60 mg kg-' day-' that
survived beyond day 10 (the upper limit for acute toxicity-
related death), one delayed death was observed on day 48
(after a dose of 66 mg kg-', q4d x 3). No particular
macroscopic features were found at autopsy.
Table I Characteristics of the four human pPNET and neuroblastoma xenografts
Xenograft SK-N-MC IGR-N835 IGR-NB3 IGR-NB8
Histology PNET Neuroblastoma Neuroblastoma Neuroblastoma
Immunostaining with
NSE Negative + + + + + + + + +
Chromogranine Negative + + + +++ + + +
MIC2 Negative Negative Negative Negative
Karyotype ND 44-46, XY,der(lO)t(l:l0)(ql2;q21), 46, XY, del(l)(p21), 44-45, XY, del(l)(p35),
der(l I)t(I1;lI7)(pl l;ql 1), t(21q;21q)a del(2)(p24), +dms inv(2)(p24q14), add (6q)
N-myc (copies/haploid genome) 1 25 14 5
mdrl expression (a.u.) - - 10 22
In vivo take rate from a 298/310 (96%) 345/368 (94%) 42/52 (81%) 73/74 (99%)
s.c. implant
aAspreviouslyreported (Bettan-Renaud etal., 1989); PNET, primitive neuroectodermal tumour; negative, nostaining; + + +, morethan 30% of
cells stained; a.u., arbitrary unit; -, absence ofoverexpression; ND, not done. Take rate is defined as number ofanimals with tumour/number of
transplanted animals.
a
-1- del(lp) -2- del(2p)
b
Mitosis with DMS (arrow)
-1- del(lp) -2- inv(2) -6- add (6q)
Figure 3 Partial karyotypes of the two newly derived neuroblastoma xenografts (a) chromosome markers of IGR-NB3 (DMS,
double minute chromosome). (b) Chromosome marker found in IGR-NB8 xenograft and patient tumour removed after
chemotherapy.Anti-tumour activity of CPT-JJ
SK-N-MC was found to be the most sensitive xenograft of
the four models tested, with 100% complete regressions and
the longest tumour growth delays at the maximum tolerated
dosage, regardless of the schedule (Table II). With the
intermittent schedule, the maximum tolerated dose was
45 mg kg-' injection (total dose, 135 mg kg-'). This dosage
produced seven out of eight SK-N-MC tumour-free survivors
on day 122. The daily x 5 schedule allowed a higher dose to
be administered, i.e. 40 mg kg-' injection (total dose,
200 mg kg-'). This dosage produced eight out of eight SK-
N-MC tumour-free survivors (Figures 4a and b). In addition,
CPT-1 1 activity was clearly sustained when administered at a
lower dosage (27 mg kg-' day-' x 5) with 100% tumour-free
survivors on day 121.
CPT-11 was also very active against both IGR-NB3 and
IGR-NB8, two neuroblastoma models overexpressing the
mdrl gene. Using the daily schedule at the highest dose
tested, complete regressions (38% and 100%) with tumour
growth delays of 42 and 46 days were achieved in IGR-NB3
and IGR-NB8 respectively (Figure 4e-h). The anti-tumour
activity against IGR-NB8 was clearly retained at a lower
dosage.
The least sensitive model was the mdr-negative IGR-N835
neuroblastoma xenograft. The best schedule was the daily x 5
schedule, as seen with the SK-N-MC model. At the highest
dosage tested, one partial and seven out of eight complete
regressions were obtained with a 38 day tumour growth delay
(Figure 4c and d). Again, activity persisted at lower doses.
When the same total dose level (135 mg kg-') was
considered, the intermittent schedule (q4d x 3) induced only
one CR out ofeight tumours with a TGD of 12 days whereas
the daily schedule (one daily dose for 5 days) induced six out
of eight CRs with a TGD of 26 days (Table II).
Activity of other anti-cancer drugs
The SK-N-MC xenograft model, which was highly sensitive
to CPT-11, was also highly sensitive to cyclophosphamide
and thiotepa, which induced nine out of ten and six out of
eight long-term tumour-free survivors respectively (Table III).
Cisplatin, given at its highest non-toxic dose (7 mg
kg-' day-' x 2) induced one CR out of eight tumours and
one tumour-free survivor. Etoposide and taxol failed to
induce any complete tumour regression or any significant
tumour growth delay. IGR-N835 was sensitive to alkylating
agents with significant TGDs of 13, 21 and 28 days being
observed with thiotepa, cisplatin and cyclophosphamide
CPT-11 against neuroblastoma xenografts
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respectively (Table III). In addition, complete regressions
were obtained with cyclophosphamide and cisplatin. Thus,
alkylating agents at the tested doses were less active than
CPT-11 against the neuroblastoma IGR-N835 xenograft.
Etoposide and taxol failed to demonstrate any anti-tumour
activity against IGR-N835.
Discussion
Human tumour xenografts are now well-established tools for
preclinical screening ofanti-cancer drugs and an integral part
of the current NCI and EORTC disease-oriented strategies
for drug screening (Winograd et al., 1988). Xenografts are
believed to predict the histological type of human cancers
likely to be sensitive or resistant to a new anti-cancer agent.
This property led to the design of so-called 'preclinical phase
II studies' (Boven et al., 1988) of anti-cancer drugs, which
would serve to orient future clinical development targeting
histology. Such disease-oriented preclinical development of
new drugs was considered particularly applicable to
paediatric oncology for two major reasons. Cancer is rare
in children and survival rates are high. Consequently, the
number of children suffering from cancer who are eligible for
phase I and II studies is considerably lower than that of
adults eligible for such studies. Preclinical phase II studies
against specific paediatric tumour xenografts may help to
select new drugs whose clinical development should be
rapidly promoted in paediatric oncology.
Our first objective was to establish subcutaneous xenograft
models for the preclinical evaluation of new anti-cancer drugs
against neuroblastoma and pPNET. The panel comprises one
PNET (SK-N-MC) and three neuroblastoma models. SK-N-
MC was at the outset classified as a neuroblastoma cell line
(Biedler et al., 1973). Later on, this cell line was reclassified in
the peripheral PNET histology group because of the absence
of N-myc amplification and the presence of a t(11;21)
reciprocal translocation (Chen et al., 1995). This was
confirmed in our study by the presence of the EWS-FLI
fusion transcript in xenografts derived from the SK-N-MC
cell line. Although often used as a neuroepithelioma cell line,
the histological features of SK-N-MC xenografts correspond
to those ofan immature peripheral PNET, without the classic
morphological and immunohistochemical (staining with
MIC2 antibodies) features of a neuroepithelioma.
The panel of neuroblastoma xenograft models used in this
study comprises a previously reported in vitro cell line (IGR-
N835) established in vivo (Bettan-Renaud et al., 1989), and
two newly derived neuroblastoma xenograft lines (IGR-NB3
Table II Anti-tumour activity of i.v. CPT-l1 against pPNET and neuroblastoma xenografts
DT
mean+s.d. Dose Total dose Toxic TGD Tumour-free
Xenograft (days) (mg kg-l day-1) Schedule (mg kg'-) n BWL (%) deaths CR PR (days) survivors
SK-N-MC 5.8±2.9 45 q4dx3 135 8 1.8 0 8 - >105 7/8 on day 122
66 q4dx3 198 8 1.5 3 5 - >105 4/5 on day 122
100 Single 100 8 NA 5 0 3 31 0/3
SK-N-MC 8.8+2.9 27 Dailyx5 135 8 1 0 8 - >96 8/8 on day 121
40 DailyxS 200 8 3 0 8 >96 8/8 on day 121
60 Dailyx5 300 8 14 5 3 - >96 3/8 on day 121
IGR-N835 3.8+1.2 45 q4d x 3 135 8 0 1 1 3 12 0/7
60 q4d x 3 180 8 0 2 0 9 13 0/6
IGR-N835 3.5+0.5 27 Daily x 5 135 8 1.4 0 6 2 26 0/8
40 Daily x 5 200 8 0.5 0 7 1 38 0/8
IGR-NB8 3.3±1.5 27 Daily x 5 135 10 0 0 10 - 39 0/10
40 Daily x 5 200 10 0.5 0 10 - 46 0/10
IGR-NB3 10+4.4 40 Dailyx5 200 8 11 0 3 4 42 0/8
Doubling time was measured in each control group during the exponential phase of tumour growth; n, number of animals per group; BWL,
maximal body weight loss; CR, complete tumour regression; PR, partial tumour regression; TGD, tumour growth delay; NA, not available.CPT-11 against neuroblastoma xenograft
G Vassal et al
542
and IGR-NB8). IGR-N835 was established from a previously derived from primary refractory non-metastatic neuroblasto-
treated metastatic neuroblastoma with N-myc amplification. mas with N-myc amplification; (2) they exhibited diploidy or
The two new xenograft models also exhibited the features paradiploidy, chromosome lp deletion, N-myc amplification
consistent with poor prognosis neuroblastomas: (1) they were and overexpression of mdrl. This is in good agreement with
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IVpreviously published studies of neuroblastoma xenografting.
Recently, George et al. (1993) reported their experience of
xenografting 58 neuroblastomas into Balb/c nude mice with
an overall engraftment success rate of 34%. They showed
that xenografts could exclusively be established from tumours
with unfavourable histology. Most of the xenografts
exhibited N-myc amplification and lp abnormalities. More-
over, the survival of patients with a tumorigenic tumour was
significantly worse than that of patients with a non-
tumorigenic tumour. The three neuroblastomas xenograft
models included in the present experimental therapeutic study
are neuroblastomas with a poor prognosis in children.
Among the new anti-cancer drugs in clinical development
in adults, the DNA-topoisomerase I inhibitors are of
particular interest for the treatment of children with cancer.
These new drugs are semisynthetic derivatives of camptothe-
cin, the leading compound in this new class (Potmesil, 1994).
DNA-topoisomerase I, their intranuclear target, has,
hitherto, never been the target of any of the anti-cancer
drugs currently used in chemotherapy protocols in paediatric
oncology. Camptothecin activity is mainly directed against
proliferating cells. Unlike adult cancers, most paediatric
tumours are characterised by a rapid proliferation rate and
thus may be sensitive to topoisomerase I inhibitors. Three
camptothecin derivatives are under investigation in adult
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clinical trials: CPT-11, topotecan and 9-aminocamptothecin
(Potmesil, 1994). A recent up-front phase II study of
topotecan showed a 37% response rate in children with a
stage IV neuroblastoma (Kretschmar et al., 1995). Recently,
Tanizawa showed that SN38, the active metabolite of CPT-
11, was the most potent compound in terms of in vitro
cytotoxicity and the extent of DNA damage, compared with
topotecan, camptothecin and 9-aminocamptothecin (Taniza-
wa et al., 1994).
The work presented here demonstrates that CPT- 1 is
highly active against three neuroblastoma xenografts as it
induced complete regressions and significant tumour growth
delays in all models treated with short-term schedules (less
than 2 weeks). In addition, the pPNET xenograft model
proved to be highly sensitive with 100% of tumour-free
survivors. The intermittent schedule was consistently found
to be less effective than the daily schedule. CPT-1 1 is clearly
active against neuroblastoma and pPNET xenografts, as its
anti-tumour activity was retained at doses lower than the
optimal dosage. These results are in good agreement with
those of Komuro et al. (1994) who showed that CPT-11,
administered i.p., induced significant tumour growth inhibi-
tion in the TNB9 neuroblastoma xenograft model, although
no complete tumour regression was reported. CPT-11 was
also found to be active against other paediatric cancer
Table III Anti-tumour activity of five anti-cancer drugs against SK-N-MC
DT
Xenograft/ mean ±s.d. Dose Schedulel Total dose Toxic TGD Tumour-free
drug (days) (mgkg- day-') route (mgkg-1) n BWL (%) deaths CR PR (days) survivors
Cyclophos- 5.4+0.7 400 Single/i.p. 400 10 0 0 9 1 >107 9/10 on day 120
phamide
Thiotepa 6.2+1.6 24 Single/i.p. 24 9 0.5 1 8 - >120 6/8 on day 120
Cisplatin 7.3 ±2.3 5 day 0, day 4/ 10 8 0 0 1 - 9 1/8 on day 122
i.v.
7 day 0, day 4/ 14 8 5 0 1 2 14 1/8 on day 122
i.v.
10 day 0, day 4/ 20 8 13 1 3 3 25 2/7 on day 122
i.v.
Etoposide 8.0±1.1 17 DailyxS/ i.v. 85 8 4 0 0 0 0 0/8
25 DailyxS/ i.v. 125 8 13 2 0 0 0 0/6
Taxol 6.2+3.6 12 Dailyx7/ i.p. 84 5 0 0 0 0 5 0/5
16 Dailyx7/ i.p. 112 5 3 0 0 0 16 0/5
18 Dailyx7/ i.p. 126 5 14 4 0 0 NA
Doubling time was measured in each control group during the exponential phase of tumour growth; n, number of animals per group; BWL,
maximal body weight loss; CR, complete tumour regression; PR, partial tumour regression; TGD, tumour growth delay; NA, not available.
Table IV Anti-tumour activity of five anti-cancer drugs against IGR-N835
DT
Xenoraft/ mean +s.d. Dose Schedulel Total dose Toxic TGD Tumour-free
drug (days) (mgkge day-') route (mgkgel) n BWL (%) deaths CR PR (days) survivors
Cyclophos- 3.2±0.9 400 Single/i.p. 400 8 0 0 2 2 28 0/8
phamide
Thiotepa 3.2 ±0.8 24 Single/i.p. 24 10 0 0 0 5 13 0/10
Cisplatin 3.5 ±0.9 3.5 day 0, day 4/ 7 8 3 0 0 0 12 0/8
i.v.
5 day 0, day 4/ 10 8 8 0 1 5 19 1/8 onday 151
i.v.
7 day 0, day 4/ 14 8 12.7 0 5 3 21 1/8 onday 151
i.v.
Etoposide 4.1+0.6 17 Daily x 5/i.v. 85 8 5.5 0 0 0 4 0/8
25 Daily x 5/i.v. 125 8 - 8 NA NA
Taxol 3.5+1.6 12 Daily x 7/i.p. 84 9 0 0 0 0 3 0/9
16 Daily x 7/i.p. 112 9 8 0 0 0 10 0/9
20 Daily x 7/i.p. 140 9 10 9 0 0 NA
Doubling time was measured in each control group during the exponential phase of tumour growth; n, number of animals per group; BWL,
maximal body weight loss; CR, complete tumour regression; PR, partial tumour regression; TGD, tumour growth delay; NA, not available.CPT-11 against neuroblastoma xenografts
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xenografts, including rhabdomyosarcomas (Houghton et al.,
1993) and medulloblastomas (Vassal et al., 1994). Houghton
showed that CPT-11 active against five of six childhood
rhabdomyosarcoma xenograft models, even at dosages below
the maximum tolerated dose (MTD) (Houghton et al., 1993).
In addition, a recent study suggested that the use of
protracted schedules may increase the therapeutic activity of
CPT-11 (Houghton et al., 1995).
Previous studies have shown that CPT-11 is active against
multidrug-resistant cell lines (Kunimoto et al., 1987; Tsuruo
et al., 1988). Houghton also found that CPT-11 retained its
activity in vivo against a vincristine-resistant rhabdomyosar-
coma xenograft (Houghton et al., 1993). This is important as
the human mdrl gene is overexpressed in neuroblastomas and
several clinical studies have noted a relationship between
mdrl overexpression and a poor prognosis in neuroblastoma
patients (Bourhis et al., 1989; Chan et al., 1991). It is
noteworthy that our study demonstrates CPT-11 activity
against neuroblastoma xenografts overexpressing the human
mdrl gene.
The activity offive anti-cancer drugs was evaluated against
SK-N-MC and IGR-N835 to validate our models in
comparison with the established chemosensitivity of pPNETs
and neuroblastomas in children. Cyclophosphamide and
etoposide are currently used in conventional chemotherapy
protocols to treat patients with neuroblastoma and Ewing's
sarcoma (Hayes et al., 1989; Meresse et al., 1993; Kushner et
al., 1994). Cisplatin is a major drug used to treat
neuroblastoma (Philip et al., 1987; Kushner et al., 1994).
Thiotepa is an alkylating agent used at a high dose before
autologous bone marrow stem cell support in adult and
childhood malignancies (Wolff et al., 1990). Taxol, a new
anti-cancer agent, is currently being investigated in phase I
and II clinical trials in children with solid tumours and
leukaemia (Hurwitz et al., 1993; Kretschmar et al., 1995). The
two xenografts were clearly sensitive to alkylating agents
(cyclophosphamide, thiotepa) and cisplatin, with SK-N-MC
being more sensitive than IGR-N835. This is in good
agreement with the established sensitivity of pPNETs and
neuroblastomas (Hayes et al., 1989; Meresse et al., 1993;
Kushner et al., 1994). Conversely, the two xenografts were
refractory to taxol and etoposide. A recent up-front phase II
study on taxol has shown an 18% response rate in
neuroblastoma patients (Kretschmar et al., 1995). Etoposide
is widely used in paediatric oncology in combination with
other drugs such as cyclophosphamide and platinum
compounds (cisplatin or carboplatin) (Philip et al., 1987;
Meresse et al., 1993). However, phase II studies of single-
agent etoposide showed very low response rates (<10%) in
neuroblastoma and Ewing's sarcoma patients (Kung et al.,
1988). Thus, the CPT- 11 activity was observed in two
xenografts, which seems to reflect the sensitivity of
neuroblastomas and pPNETs observed in children.
In conclusion, CPT-l1 was found to be highly active
against pPNET and neuroblastoma xenografts that exhibited
the biological features of poor prognosis tumours in children.
The high activity of CPT- 11 observed in this study compared
with that of conventional anti-cancer drugs used to treat
children with neuroblastoma and pPNET suggests that CPT-
11 deserves prompt evaluation in paediatric oncology.
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